Mumbai and London, 6 April 2018: Quinag Acquisition (FDI) Limited, a company backed by funds advised by Apax Partners (“the Apax Funds”), today announced that it has entered into a definitive agreement to acquire a controlling stake in Healthium MedTech Private Limited (“Healthium” or the “Company”, previously known as “Sutures India”), the leading independent medical devices player in India. The controlling stake was acquired from existing shareholders including TPG Growth, CX Partners, and founding shareholders. The transaction is subject to customary approvals. The financial terms of the transaction are not being disclosed.

Founded in 1992, Healthium manufactures and sells a broad range of medical devices and consumable products including wound closure products, minimally invasive products including endo surgery and arthroscopy consumables, and urology products. The Company’s key brands include Trusynth, Truglyde, Trubond, and Sironix, amongst others.

Through its strong pan-India distribution presence under the Sutures India division, Healthium sells its products across large and corporate hospitals, nursing homes, and government hospitals and institutions, and services over 10,000 hospitals across the country. Backed by the Apax Funds, Healthium plans to further deepen its presence in the Indian market and broaden its portfolio of specialty medtech products.

Healthium has a significant and growing international business with exports to over 50 countries. With an already strong presence in the urology market in the UK, under the Clinisupplies division, Healthium has also recently and successfully launched a portfolio of wound closure products under the Q-Close brand.

Healthium will be the eighth investment in India for the Apax Funds over the past 11 years. Including this transaction, the Apax Funds have invested just under $2bn of equity in the country. The investment in Healthium marks the second investment in the healthcare space for the Apax Funds in India, following the investment in Apollo Hospitals.

Shashank Singh, Partner at Apax Partners and Head of Apax’s India office, said: “Healthcare is a key focus area for Apax in India given secular tailwinds around healthcare spend and government initiatives focused on affordable and universal healthcare. Healthium, with its strong IP and domestic manufacturing base, is well positioned to improve healthcare access and drive excellence in local manufacturing under the Make in India programme. The opportunity is to create a medtech platform of scale to deliver a broad portfolio of products in the Indian market, and we are excited to partner with the management team of Healthium to deliver this vision.”

Steven Dyson, Partner at Apax Partners and Global Co-head of Healthcare at Apax, said: “Apax has strong experience in medical devices companies globally with several large businesses such as Vyaire, Acelity and Syneron Candela in the Apax Funds’ portfolio. Healthium is a well-established brand selling high quality products at affordable prices, which is necessary in a market like India. We see a great opportunity to further expand its product portfolio and create India’s leading medical devices company.”

Matt Hobart, Partner at TPG Growth and leader of the fund’s Healthcare practice globally, said:  “TPG Growth has invested in a significant number of healthcare provider businesses around the world, from urgent care clinics and travel nurse staffing in the United States to world-class cancer clinics and specialty mother and child centers in India. Thematically, we have always been focused on investing behind companies that offer high-quality products and services with a focus on value. From the time we invested five years ago, Healthium has always delivered extremely well on that quality-cost equation. We are very pleased to have grown Healthium into one of the leading medtech platforms in India and are confident that the Company will continue to scale effectively for years to come.”

Apax was advised by Kirkland & Ellis (legal counsel), Khaitan & Co (legal counsel), and PwC (accounting and tax advisor). TPG Growth was advised by Shardul Amarchand Mangaldas (legal counsel), Deloitte (accounting and tax), and Goldman Sachs.

About Healthium MedTech Private Limited
Healthium is India’s leading medical devices player, manufacturing and marketing several surgical and medical consumables including surgical sutures, staplers, suturing needles, other wound closure products, surgical gloves, urology products and a range of minimally invasive solutions. Healthium is headquartered in Bangalore and has 5 manufacturing locations across the country. The Sutures India division of the company has a strong sales and distribution network in India comprising over 400 sales personnel and over 1,500 distributors. Clinisupplies, the UK division of Healthium, is a leading medical devices player in the UK, marketing and selling urology products, surgical sutures and other wound care products. Healthium also has significant global presence with exports to over 50 countries, including the USA, France, Germany, Italy, Switzerland, Brazil, Mexico, GCC countries, Egypt, Turkey and several Asian countries. Healthium also has a large OEM business that caters to requirements of sutures and other medical device companies globally.

About Apax Partners
Apax Partners is a leading global private equity advisory firm. Over its more than 35-year history, Apax Partners has raised and advised funds with aggregate commitments of over $50 billion. The Apax Funds invest in companies across four global sectors of Tech & Telco, Services, Healthcare and Consumer. These funds provide long-term equity financing to build and strengthen world-class companies. For more information see: www.apax.com.

About TPG Growth
TPG Growth is the middle market and growth equity investment platform of TPG, the global private investment firm. With more than $13 billion of assets under management, TPG Growth targets investments in a broad range of industries and geographies. TPG Growth has the deep sector knowledge, operational resources, and global experience to drive value creation, and help companies reach their full potential. The firm is backed by the resources of TPG, which has more than $73 billion of assets under management. For more information, visit www.tpg.com.

Media Contacts

For Apax Partners:

Global Media: Andrew Kenny, Apax | +44 20 7 872 6371 | andrew.kenny@apax.com
USA Media: Todd Fogarty, Kekst | +1 212-521 4854 | todd.fogarty@kekst.com
UK Media: Matthew Goodman / James Madsen, Greenbrook | +44 20 7952 2000 | apax@greenbrookpr.com

For TPG Growth:

Global Media: Erika White, TPG | +1 415-743-1550 | media@tpg.com
India Media: Snigdha Nair, Adfactors |+91 9920481191 | snigdha.nair@adfactorspr.com

Finnish digital health company Kaiku Health Oy, which provides intelligent patient monitoring software for healthcare providers across Europe, has closed a €4.4 million funding round. The investment was led by Debiopharm Innovation Fund SA and Tesi with participation from Prodeko Ventures Oy and existing investors Reaktor Ventures Oy, Metsola Ventures Oy, and Athensmed Oy.

Kaiku Health offers intelligent patient monitoring software for healthcare providers. Structured capture and analysis of patient-reported data enables clinicians to evaluate the effectiveness of therapies and to detect and treat health problems early. Kaiku Health platform is used in routine care by over 30 clinics in Switzerland, Germany, Italy, Sweden, and Finland, and has been used by 64,000 patients (March 2018).

“We have seen the significant positive impact our patient monitoring platform can have on people’s health”, comments Lauri Sippola, Kaiku Health CEO and Co-Founder. “This funding allows us to provide our platform to a growing number of healthcare providers and patients internationally. It is important that our investors also bring an extraordinary understanding of healthcare, life sciences and digitalization.”

“We are excited about the impact digital technologies will have on the patient journey and are particularly enthusiastic to help take the digital therapeutic approach in oncology out of the lab and onto the market where the benefits of this high frequency monitoring can be expected to bring real outcomes improvement”, says Tanja Dowe, CEO at Debiopharm Innovation Fund.

“We have studied the Finnish digital health sector thoroughly and found it extremely interesting from an investor’s point of view”, adds Joni Karsikas, Investment Manager at Tesi. “The Kaiku Health team impressed us with its strong technological know-how, for instance in the use of artificial intelligence. Kaiku Health has strong international customer references and a broad user-base for a young health-tech company.”

Digital patient monitoring can improve quality of life and reduce costs of healthcare

Recent research¹ has shown that collecting patients’ subjective experiences and turning them into structured data can have significant impact on care outcomes. Kaiku Health’s intelligent digital platform can be applied for monitoring patient-reported outcomes in several medical specialties. Its unique algorithms screen patient’s symptom data, alert care team and trigger personalized instructions for patients. Structured real-world data on the efficacy of therapies allows early interventions and personalized care.

For further information, please contact:

Kaiku Health
Lauri Sippola, CEO & Co-Founder
lauri.sippola@kaikuhealth.com
Tel: +358 40 744 7481

Tesi
Joni Karsikas, Investment Manager
joni.karsikas@tesi.fi
Tel: +358 40 827 0395

Debiopharm Group
Christelle von Büren
Communication Coordinator
christelle.vonburen@debiopharm.com
Tel: +41 (0)21 321 01 11

Pictures: media.kaikuhealth.com

1 References
Basch E, Allison MD, Mark GK, Howard IS, Clifford AH, Paul S, (2015). Symptom Monitoring With Patient- Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial, J Clin Oncol 2016: 34(6), 557–565.
Basch E, Deal AM, Dueck AC, Scher HI, Kris MG, Hudis C, Schrag D. Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment. JAMA. 2017 Jul 11; 318(2): 197-198.

About Kaiku Health
Kaiku Health (previously Netmedi Oy) is a digital health company aiming to improve quality of life and reduce costs of healthcare through data science. We are digitizing the patient monitoring and easing the adoption of Patient-Reported Outcomes in several therapy areas. Our pioneering patient monitoring platform is used in routine care by over 30 clinics in Europe.
Founded in 2012, Kaiku Health has raised over 6 million euros in total funding. Kaiku Health’s revenue in 2017 was approximately €0,7 million. We are headquartered in Helsinki, but our people also harbor in Frankfurt and Stockholm. For more information, please visit www.kaikuhealth.com and connect with us at Twitter @KaikuHealth.

About Debiopharm Innovation Fund SA
Part of Debiopharm Group™ – a Swiss-headquartered global biopharmaceutical group including five companies active in the life science areas of drug development, GMP manufacturing of proprietary drugs, diagnostic tools and investment management – Debiopharm Innovation Fund’s mission is to invest in companies developing innovative therapeutics, diagnostics and smart data solutions that change the way we develop drugs and treat patients. Since 2008, the company has invested nearly USD 100 million and led 10 out of the 14 last investment rounds in its portfolio companies.
For more information, please visit www.debiopharm.com
We are on Twitter. Follow us @DebiopharmNews 

About Tesi
Tesi (Finnish Industry Investment Ltd) is a venture capital and private equity company that accelerates companies’ success stories by investing in them directly and via funds. Tesi always invests together with other investors, providing them with access to high quality deal-flow in Finland. Our investments under management total €1.2 billion and we have altogether 700 companies in portfolio. www.tesi.fi/ @TesiFII

Eurazeo Patrimoine, the Eurazeo division specializing in investments in tangible assets, is pleased to Announce the acquisition of C2S Group from Bridgepoint. C2S Group is the eighth largest private clinic operator in France and a regional leader in Auvergne, Rhône-Alpes and Burgundy Franche-Comté.

Capitalizing on recent investments in modernizing the group and improving its operating performance, C2S will continue to accelerate its development strategy, particularly through external growth and confirm its position as a benchmark health care provider in the Central-Easternregion. It will be supported by Eurazeo Patrimoine’s experience in accompanying companies, combined with its real estate management expertise.

Eurazeo Patrimoine and Bridgepoint signed an agreement in January 2018 for the purpose of this transaction. Eurazeo Patrimoine has currently invested c.€103 million for 87% of the share capital, alongside management. Group medical practitioners and a minority co-investor are expected to enter the share capital at a later date.

***

About C2S Group

C2S Group is the eighth largest private clinic operator in France and a regional leader in Auvergne, Rhône-Alpes and Burgundy Franche-Comté. It operates 11 clinics, primarily specializing in short and medium-length stays in general medicine, surgery and follow-up care. It also owns the buildings for seven of its clinics. The group has around 500 medical practitioners, who are partners in the group’s governance and nearly 1,800 employees. In 2017, it treated over 250,000 patients (75% as outpatients) and reported revenue of €161 million.

About Eurazeo

With a diversified portfolio of approximately €15 billion in assets under management, including €1 billion from third parties, Eurazeo is a leading global investment company with offices in Paris and Luxembourg, New York, Shanghai and Sao Paulo. Its purpose and mission is to identify, accelerate and enhance the transformation potential of the companies in which it invests. The firm covers most private equity segments through its five business divisions – Eurazeo Capital, Eurazeo Croissance, Eurazeo PME, Eurazeo Patrimoine and Eurazeo Brands. Its solid institutional and family shareholder base, robust financial structure free of structural debt, and flexible investment horizon enable Eurazeo to support its companies over the long term. As a global long-term shareholder, the firm offers deep sector expertise, a gateway to global markets, and a stable foothold for transformational growth to the companies it supports.

>

Eurazeo is listed on Euronext Paris.

>

ISIN: FR0000121121

–

Bloomberg: RF FP

–

Reuters: EURA.PA

Paris, March 26, 2018: Ardian, a world-leading private investment house, and the Management and Shareholders of Groupe Bio7, announced today that they have signed an exclusive agreement for the sale of Groupe Bio7, a French-based specialist in clinical analysis, to Cerba HealthCare, a European leader in clinical pathology.

Headed by Frédéric Barroux, biologist, shareholder and founder, Groupe Bio7 is one of the leading multi-location clinical pathology groups in France. With 70 laboratories, the Group has a very strong presence in the Île-de-France region. Since 2016, Bio7 has extended its presence across the rest of France, notably in the Indre-et-Loire and Oise regions.

Groupe Bio7 is expected to generate pro forma revenue in excess of 110 million euros in 2018.

Frédéric Barroux, Chairman of Groupe Bio7, said: “We’re thrilled and very proud to enable Groupe Bio7 to continue to expand and develop. The relationship between Bio7 and Cerba HealthCare, a European leader in clinical pathology, will help our Group to broaden its range of skills and services, while continuing to apply a community-based approach designed to offer the best treatment plans for patients.”

“We deeply thank Ardian for their support and involvement in our strategic planning, their support and encouragement of our ongoing external growth, as well as the financial expertise of their teams, especially with regards to financing. The active involvement of Ardian within our Group has been a significant factor in enabling the business to double in size since 2014.”

François Jerphagnon, Head of the Ardian Expansion team, added: “Groupe Bio7’s sustained growth is testament to the long-term success of the collective and entrepreneurial project undertaken by the Groupe Bio7 teams. As an investor and shareholder, we’re especially pleased with the Group’s growth, driven both by a strong organic development of its sites, and the quality of acquisitions of various sizes identified, carried out and harmoniously integrated within the Group. The partnership with Cerba HealthCare a leading international player in clinical pathology, will ensure that this success is not only continued, but intensified.”

Catherine Courboillet, CEO of Cerba HealthCare, added: “We’re excited to welcome Bio7 to Cerba HealthCare. Under the impetus of Frédéric Barroux, the group’s biologists have built a solid and professional laboratory network. We share their values of quality, respect and innovation, as well as the same vision of the future of medical biology. Together, we’ll continue to build a model of proximity biology and expertise that places the patient at the heart of healthcare.”

LIST OF PARTIES INVOLVED

• Cerba HealthCare (Catherine Courboillet, Cyril Dubreuil, Jérôme Thill)
• Groupe Bio7 (Frédéric Barroux, Florence Pajot, Stéphane Konkuyt)
• Ardian Expansion (François Jerphagnon, Marie Arnaud-Battandier, Arthur de Salins)
• Partners Group (Christoph Rubeli, Kim Nguyen, Remy Hauser, Christopher Mauss)
• PSP Investments (Simon Marc, Patrick Daignault, Philippe Bouchard, Mia Morisset)

Advisors:

• Legal advisor to Cerba HealthCare: Goodwin Procter (Maxence Bloch, William Robert)
• Legal advisor to Management Groupe Bio7 and Ardian: Latham & Watkins (Olivier du Mottay, Louis Paumier, Marion Lebastard)
• Financial advisor to Management Groupe Bio7 and Ardian: Hottinguer Corporate Finance (Pierre de Bousingen, Djilali Bou-abdallah, Arthur Gautier)

ABOUT ARDIAN

Ardian is a world-leading private investment house with assets of US$67bn managed or advised in Europe, North America and Asia. The company is majority-owned by its employees. It keeps entrepreneurship at its heart and focuses on delivering excellent investment performance to its global investor base.
Through its commitment to shared outcomes for all stakeholders, Ardian’s activities fuel individual, corporate and economic growth around the world.

Holding close its core values of excellence, loyalty and entrepreneurship, Ardian maintains a truly global network, with more than 490 employees working from 13 offices across Europe (Frankfurt, Jersey, London, Luxembourg, Madrid, Milan, Paris and Zurich), North America (New York, San Francisco) and Asia (Beijing, Singapore, Tokyo). It manages funds on behalf of about 700 clients through five pillars of investment expertise: Fund of Funds, Direct Funds, Infrastructure, Real Estate and Private Debt.

Follow Ardian on Twitter @Ardian

www.ardian.com

ABOUT CERBA HEALTHCARE

A European leader in clinical pathology, the group is also involved in three complementary segments:
– local clinical pathology—mainly in France, Belgium, Luxembourg, Italy, and the United Arab Emirates, through a network of 300 laboratories, 150 sampling centres, and 50 technical facilities;
– specialised clinical pathology—through Laboratoire Cerba, its original laboratory, serving more than 50 countries in Europe, Africa, and Asia;
– central lab testing for clinical trials—essential to the development of new molecules by the pharmaceutical and biotechnology industry—through its subsidiaries set up across the 5 continents.
The group recently diversified through the creation of Cerba Vet, securing a position on the market of veterinary clinical pathology and genetics.
Cerba HealthCare has over 4,500 employees, including 430 medical pathologists.
In addition to the biologists and managers of the Group, since April 2017, Cerba HealthCare’s shareholders include the global private markets investment management firm, Partners Group, acting on behalf of its clients, and the Public Sector Pension Investment Board (PSP Investments), one of Canada’s largest pension investment managers.
www.cerbahealthcare.com

CONTACTS PRESSE

ARDIAN
Headland
Carl Leijonhufvud

cleijonhufvud@headlandconsultancy.com
Tel: +44 020 3805 4827

PDF version

Leading Benefit Solutions Provider Will Become Anchor Business for Ascensus’ Newly Formed Health Division

DRESHER, PA—March 20, 2018— Ascensus, a technology-enabled service provider that helps more than 7 million Americans save for the future, has entered into an agreement to acquire Chard Snyder. Chard Snyder, which will serve as the anchor business for Ascensus’ newly formed Health division, is a third-party administration firm that services consumer directed health (CDH) plans including health savings accounts, health reimbursement arrangements, and flexible spending accounts. It also offers benefit continuation services like COBRA and FMLA leave administration along with retiree billing administration and commuter benefits.

Based in Mason, Ohio, Chard Snyder provides employee benefit solutions to more than 1,400 employers throughout the United States in sectors that include Higher Education, Healthcare, Municipalities, Manufacturing, and Banking & Financial. With a 30-year track record of helping clients successfully navigate diverse and complex regulatory mandates, the firm assists employers and their employees in meeting their health benefit needs by making benefit plans easy to understand.

“When looking at Chard Snyder, we identified a market leader in the CDH space with an outstanding market and client reputation,” states David Musto, Ascensus’ president. “Adding their employee benefits expertise to our suite of service offerings positions Ascensus to better achieve our mission of helping Americans save for retirement, education, and health needs.”

“This is a core business for us, and it will significantly expand our service offerings to our current clients, advisors, and partners,” continues Musto. “I’m pleased to welcome Chard Snyder’s management team and their associates to our organization.”

“Chard Snyder’s difference has always been our people and our ability to maintain authentic customer experiences,” says Joy Snyder, president of Chard Snyder. “As part of Ascensus, we’ll continue to provide a no-noise atmosphere to our advisors, clients, and business partners via a highly personalized approach that incorporates flexibility and customization in addition to technology and compliance expertise.”

“Chard Snyder is an ideal anchor business for Ascensus’ expansion into the CDH and benefit administration space,” says Raghav Nandagopal, Ascensus’ executive vice president of corporate development and M&A. “With this acquisition, we are aligning to the market trends of the consolidation of savings, retirement, and health solutions—and we are delighted with the potential growth runway it entails.”

“In addition to possessing a scalable technology platform and outstanding service delivery capabilities, Chard Snyder’s core values align nicely with Ascensus’ client-first approach,” continues Nandagopal. “We believe they provide a foundation for strong organic growth in our newly formed Health division, and we will look for opportunities to enhance this and other areas of our business to support Ascensus’ immediate and long-term growth plans.”

About Ascensus

Ascensus helps more than 7 million Americans save for the future—retirement, education, and healthcare—through technology-enabled solutions. With more than 35 years of experience, the firm offers tailored solutions that meet the needs of asset managers, banks, credit unions, state governments, financial professionals, employers, and individuals. Ascensus supports over 54,000 retirement plans, more than 4 million 529 education savings accounts, and a growing number of ABLE savings accounts. It also administers more than 1.5 million IRAs and health savings accounts. As of December 31, 2017, Ascensus had over $163 billion in total assets under administration. For more information about Ascensus, visit ascensus.com.

###

MEDIA INQUIRIES:

Roberta Hess
Ascensus
Senior Vice President Marketing & Communications
Tel: 215-648-1426
Media@ascensus.com

Chicago and London, March 19, 2018 – Funds advised by Apax Partners (“the Apax Funds”) today announced they have entered into a definitive agreement to purchase from BD (Becton, Dickinson and Company) its remaining ownership interest in Vyaire Medical, Inc., a global leader in respiratory care.

Upon completion of the transaction, which is expected to occur by the end of April (subject to customary closing conditions), Vyaire Medical will be 100% controlled by the Apax Funds.

The Apax Funds acquired a majority stake in Vyaire Medical, previously BD’s Respiratory Solutions business, in October 2016. BD initially retained a minority stake in the newly independent company through a joint venture with the Apax Funds. Today, Vyaire Medical is the leading pure play medical device company in the respiratory space. With approximately $800 million in annual sales, Vyaire Medical is active in manufacturing and distributing both respiratory and anesthesia/surgical consumables as well as capital equipment for respiratory diagnostics and ventilation. Vyaire thereby supports the care of chronic and acute respiratory patients as well as the airway management of surgical patients across the healthcare continuum.

Steven Dyson, Partner at Apax Partners, said, “Since the Apax Funds acquired a majority stake in Vyaire Medical in October 2016, strong progress has been made by the business. A new senior management team led by CEO Dave Mowry has established key functions, delivered operational improvements, upgraded commercial capabilities and made two accretive acquisitions. It was on the basis of this progress, and the promise that we continue to see for the business, that we sought to acquire BD’s minority stake. We would like to thank the BD team for being excellent partners and supporting the company through its history.”

Dave Mowry, Vyaire’s President and Chief Executive Officer, said, “We are pleased with the progress our team has achieved over the past 18 months in establishing Vyaire Medical as a focused and leading global respiratory solutions provider with the objective of improving patient outcomes and increasing value for our customers. Our success in standing up Vyaire Medical as an independent company also has been made possible by the support of BD and the contributions from Apax Partners, which has provided our team with a range of capabilities, including the expertise from its Operational Excellence team of dedicated functional specialists.”

About Vyaire Medical
Vyaire Medical supports and improves the lives of patients with a laser-focus on improving patient outcomes and increasing value for customers. The Chicago, IL.-headquartered company was formed in October 2016 to serve healthcare customers with innovative device and service solutions across the respiratory and anesthesia continua of care. Vyaire’s legacy brands have a 65-year track record of pioneering, innovating, and advancing respiratory diagnostics, ventilation, and anesthesia delivery & patient monitoring. From industry-pioneering brands that include Bird, Bear, and Jaeger to respected industry leaders AirLife®, Vital Signs®, Viasys, and many others – Vyaire Medical has nearly 27,000 distinct part numbers recognized, trusted and preferred by specialists in the respiratory therapy and anesthesiology healthcare markets worldwide. Learn more at www.vyaire.com.

About Apax Partners
Apax Partners is a leading global private equity advisory firm. Over its more than 35-year history, Apax Partners has raised and advised funds with aggregate commitments of over $50 billion. Apax Partners’ Main Buyout Funds invest in companies across four global sectors of Healthcare, Tech & Telco, Services and Consumer. These funds provide long-term equity financing to build and strengthen world-class companies. Apax Partners has a strong track record in corporate carve-outs, supported by its Operational Excellence Practice, a team of dedicated operating specialists who support deal teams and drive value creation in the portfolio.

For more information see www.apax.com.

Media Contacts  

For Apax Partners:

Global Media: Andrew Kenny, Apax | +44 20 7 872 6371 | andrew.kenny@apax.com

USA Media: Todd Fogarty, Kekst | +1 212-521 4854 | todd.fogarty@kekst.com

UK Media: Matthew Goodman / James Madsen, Greenbrook | +44 20 7952 2000 | apax@greenbrookpr.com

Nordic Capital Fund IX (“Nordic Capital”) today announced the signing of the acquisition of Ober Scharrer Group (“OSG” or “the Group”). OSG is Germany’s largest provider for treatments for major causes of blindness and visual impairment as well as non-invasive treatments and diagnosis of eye disorders.

OSG, founded in 1982 and headquartered in Fürth, Germany, offers a broad spectrum of specialised ophthalmic treatments and provides high quality medical care to both public and private patients. Key services provided are surgical treatments such as cataract operations and Intravitreal Operative Drug Application (IVOM) for degenerative eye disorders. The Group has 900 employees performing more than 85,000 treatments per year across its c. 80 clinics in Germany.

As a leading healthcare investor with a 25-year track record of building high quality, sustainable healthcare businesses, Nordic Capital intends to support and further develop Ober Scharrer in line with its current strategy.

“The opportunity for future growth in the fragmented ophthalmic outpatient market is extensive and we are excited about the prospects as we continue to build our business. With Nordic Capital we have found a partner and owner that share our dedication to medical excellence, patient satisfaction and quality of services as well as our vision for growth. We believe Nordic Capital’s extensive experience in healthcare, both in and outside Germany, will be very valuable in the years to come,” comments Sibylle Stauch-Eckmann, CEO of OSG.

“Nordic Capital has followed this sector for several years, observing how OSG has continued to build its strong position and reputation for delivering medical excellence. Nordic Capital looks forward to investing in and supporting OSG’s further development and growth in its field of expertise where we see a strong demand for specialised, high quality centres to provide treatments,” says Joakim Lundvall, Partner at the Advisor to the Nordic Capital Funds.

With the acquisition of OSG from Palamon Capital Partners, Nordic Capital continues to build its healthcare franchise in the German speaking region. Since inception, the Nordic Capital Funds have invested in over 20 healthcare platforms across Europe and the USA.

The parties have agreed to not disclose the financial details. The transaction is subject to customary regulatory approvals.

Media contacts:

Katarina Janerud, Communications Manager
Advisor to the Nordic Capital Funds
Tel: +46 8 440 50 50
e-mail: katarina.janerud@nordiccapital.com

About Ober Scharrer Group

The Ober Scharrer Group was established in 1982 by two physicians Dr Ober and Dr Scharrer. Headquartered in Fürth, the company now has c. 80 facilities across Germany, 900 employees and delivers more than 85,000 treatments per year. Key group services include cataract operations and Intravitreal Operative Drug Application (IVOM) for degenerative eye disorders, as well as non-invasive eye treatments and the diagnosis of eye disorders. For more information on the Ober Scharrer Group refer to www.osg.de

About Nordic Capital

Nordic Capital is a leading private equity investor in the Nordic region with a resolute commitment to creating stronger, sustainable businesses through operational improvement and transformative growth. Nordic Capital focuses on selected regions and sectors where it has deep experience and a proven track record. Core sectors are Healthcare, Technology & Payments, Financial Services, Industrial Goods & Services and Consumer & Retail, and key regions are the Nordics, Northern Europe, and globally for Healthcare. Since inception in 1989, Nordic Capital has invested EUR 12 billion in close to 100 investments. The Nordic Capital Funds are based in Jersey and are advised by advisory entities, which are based in Sweden, Denmark, Finland, Norway, Germany and the UK. For further information about Nordic Capital, please visit www.nordiccapital.com